Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396
July 03, 2023 06:01 ET
|
Zealand Pharma
Company announcement – No. 27 / 2023 Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 Doses of 0.6 and 1.2 mg ZP8396...
Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism
June 30, 2023 13:32 ET
|
Zealand Pharma
Press release – No. 8 / 2023 Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism Copenhagen, Denmark, June 30, 2023 – Zealand Pharma A/S...
Total number of shares and voting rights in Zealand Pharma at June 30, 2023
June 30, 2023 11:05 ET
|
Zealand Pharma
Company announcement – No. 26 / 2023 Total number of shares and voting rights in Zealand Pharma at June 30, 2023 Copenhagen, Denmark, June 30, 2023 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL)...
Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency
June 26, 2023 02:30 ET
|
Zealand Pharma
Press release – No. 7 / 2023 Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency ...
Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions
June 24, 2023 11:35 ET
|
Zealand Pharma
Press release – No. 6 / 2023 Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions Body weight reductions reached up to a mean...
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)
June 23, 2023 17:15 ET
|
Zealand Pharma
Press Release No. 5 / 2023 Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with...
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
June 08, 2023 16:00 ET
|
Zealand Pharma
Company announcement – No. 25 / 2023 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, June 8, 2023 – Zealand Pharma A/S (“Zealand”)...
Zealand Pharma to Participate in Upcoming Healthcare Conferences
June 06, 2023 11:00 ET
|
Zealand Pharma
Press release – No. 4 / 2023 Zealand Pharma to Participate in Upcoming Healthcare Conferences Copenhagen, Denmark, June 6, 2023 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078),...
Total number of shares and voting rights in Zealand Pharma at May 31, 2023
May 31, 2023 11:05 ET
|
Zealand Pharma
Company announcement – No. 24 / 2023 Total number of shares and voting rights in Zealand Pharma at May 31, 2023 Copenhagen, Denmark, May 31, 2023 – Zealand Pharma A/S (“Zealand”)...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
May 25, 2023 16:00 ET
|
Zealand Pharma
Company announcement – No. 23 / 2023 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...